Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA

Fredrik H. Schjesvold; Nicolaas A. Bakker; Pieter Sonneveld

doi:10.1016/j.tranon.2022.101528

Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA

Fredrik H. Schjesvold^*, Nicolaas A. Bakker, Pieter Sonneveld

^*Corresponding author for this work

Hematology

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

7 Downloads (Pure)

Original language	English
Article number	101528
Journal	Translational Oncology
Volume	25
DOIs	https://doi.org/10.1016/j.tranon.2022.101528
Publication status	Published - Nov 2022

Bibliographical note

2022 The Authors. Published by Elsevier Inc.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.tranon.2022.101528Licence: CC BY-NC-ND

1-s2.0-S1936523322001875-mainFinal published version, 324 KBLicence: CC BY-NC-ND

Cite this

@article{4aed120f722e451aae858ec2bdbd02e0,

title = "Authors{\textquoteright} reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA",

author = "Schjesvold, {Fredrik H.} and Bakker, {Nicolaas A.} and Pieter Sonneveld",

note = " 2022 The Authors. Published by Elsevier Inc.",

year = "2022",

month = nov,

doi = "10.1016/j.tranon.2022.101528",

language = "English",

volume = "25",

journal = "Translational Oncology",

issn = "1936-5233",

publisher = "Neoplasia Press",

}

TY - JOUR

T1 - Authors’ reply

T2 - Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA

AU - Schjesvold, Fredrik H.

AU - Bakker, Nicolaas A.

AU - Sonneveld, Pieter

N1 - 2022 The Authors. Published by Elsevier Inc.

PY - 2022/11

Y1 - 2022/11

UR - http://www.scopus.com/inward/record.url?scp=85137398925&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2022.101528

DO - 10.1016/j.tranon.2022.101528

M3 - Comment/Letter to the editor

AN - SCOPUS:85137398925

VL - 25

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

M1 - 101528

ER -

Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this